Abstract：
BACKGROUND:Immunization programs' resilience to shocks is central to their success, but little empirical evidence documents resilience in action. We sought to characterize the decline of HPV vaccination in Denmark after negative media coverage and recovery during a national information campaign. METHODS:We conducted a population-based retrospective cohort study of all girls born in Denmark from 1997 to 2006 (N = 328,779), aged 12-15. The outcome measure was HPV vaccine uptake (first dose), as reported to the Danish national health registry from 2009 to 2019, when HPV vaccine was freely available to girls in primary care clinics in Denmark. Events that created 4 natural time periods for study were HPV vaccine reaching the uptake of other vaccines in the national program (2009), some negative media coverage of HPV vaccination (2013), extensive negative media coverage (2015), and a national information campaign about the vaccine's safety and effectiveness (2017-2019). RESULTS:In the period with some negative media coverage, HPV vaccine uptake fell to 83.6% (95% CI:78.0%-89.7%) of baseline uptake. In the period with extensive negative media coverage, uptake fell even further to 49.6% (95% CI:44.5%-55.2%) of baseline uptake. After the information campaign, HPV vaccine uptake recovered to its baseline level (109.2%, 95% CI:90.1%-132.4%) due in part to catch-up doses. Despite the recovery, an estimated 26,000 fewer girls initiated the vaccine than if uptake had not declined. CONCLUSIONS:The experience in Denmark offers one of the first opportunities to document how a nation grappled with negative media coverage of HPV vaccination and the steadying impact of action by national authorities.
journal_name
Vaccinejournal_title
Vaccineauthors
Hansen PR,Schmidtblaicher M,Brewer NTdoi
10.1016/j.vaccine.2019.12.019subject
Has Abstractpub_date
2020-02-11 00:00:00pages
1842-1848issue
7eissn
0264-410Xissn
1873-2518pii
S0264-410X(19)31661-5journal_volume
38pub_type
杂志文章相关文献
VACCINE文献大全abstract：:Pertussis is an acute respiratory infectious disease caused by the bacterium Bordetella pertussis. Although pertussis vaccination was introduced in the 1960s, pertussis is still an endemic disease in China. To better understand the genetic diversity of the Chinese B. pertussis population, we characterized 115 clinical...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2015.09.040
更新日期：2015-11-17 00:00:00
abstract：:Since the production of influenza vaccines is complicated by the continuous variation of these viruses, it would be desirable to develop vaccines that induce cross-protective immunity against influenza virus strains that circulate in subsequent winter epidemics. We have recently demonstrated that antibodies induced af...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/s0264-410x(01)00262-6
更新日期：2001-10-12 00:00:00
abstract：:Rotavirus vaccine was introduced in El Salvador in 2006 and is recommended to be given concomitantly with DTP-HepB-Haemophilus influenzae type b (pentavalent) vaccine at ages 2 months (upper age limit 15 weeks) and 4 months (upper age limit 8 months) of age. However, rotavirus vaccination coverage continues to lag beh...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2015.07.092
更新日期：2015-11-27 00:00:00
abstract：BACKGROUND:Micrurus venoms contain two main groups of toxic protein components: short-chain α-neurotoxins (SNtx) and phospholipases type A2 (PLA2). In North America, generally, the Micrurus venoms have low abundance of SNtx compared to that of PLA2s; however, both are highly toxic to mammals, and consequently both can ...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2020.12.052
更新日期：2021-02-05 00:00:00
abstract：BACKGROUND:Challenges in reaching good vaccination coverage against measles emerged in several European Union/European Economic Area Member States (EU/EEA MS) leading to progressive accumulation of susceptible individuals and outbreaks. The Burden of Communicable Diseases in Europe (BCoDE) project developed a methodolo...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2014.01.094
更新日期：2014-04-01 00:00:00
abstract：:We describe here two very potent adjuvant systems which are thought to work directly on antigen specific lymphocytes, thus by-passing the normal route for adjuvants, which is to activate antigen presenting cells (APCs) inducing release of inflammatory cytokines with resultant side effects of local and systemic reactog...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2005.01.105
更新日期：2006-04-12 00:00:00
abstract：:Pseudomonas aeruginosa is a common cause of infection in immunocompromised patients and is the major contributor to morbidity in individuals with cystic fibrosis (CF). The antibiotic resistance shown by this pathogen and morbidity in patients with chronic infection has encouraged investigations into the development of...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/s0264-410x(00)00146-8
更新日期：2000-09-15 00:00:00
abstract：:In this work, we explored the potential of cationic solid lipid nanoparticles (cSLN) as efficient adjuvants for inactivated foot and mouth disease virus (iFMDV) vaccine. The cSLN were prepared by O/W emulsion method with Compritol 888 ATO as lipid matrix, and were modified by cationic lipid Didodecyldimethylammonium b...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2020.02.004
更新日期：2020-03-04 00:00:00
abstract：BACKGROUND:Combination antiretroviral therapy (cART) is the main therapeutic management tool for HIV/AIDS. Despite its success in controlling viral load and disease progression, cART is expensive, associated with a range of significant side effects and depends for its efficacy on the patient's life-long commitment to h...
journal_title：Vaccine
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1016/j.vaccine.2013.09.057
更新日期：2013-11-19 00:00:00
abstract：:The baculovirus-insect cell expression system is a well known tool for the production of complex proteins. The technology is also used for commercial manufacture of various veterinary and human vaccines. This review paper provides an overview of how this technology can be applied to produce a multitude of vaccine cand...
journal_title：Vaccine
pub_type： 杂志文章,评审
doi：10.1016/j.vaccine.2012.01.016
更新日期：2012-02-27 00:00:00
abstract：:Adult patients with mucosal leishmaniasis (ML) were enrolled in a randomized, double-blind, placebo-controlled, dose-escalating clinical trial and were randomly assigned to receive three injections of either the LEISH-F1+MPL-SE vaccine (consisting of 5, 10, or 20 μg recombinant Leishmania polyprotein LEISH-F1 antigen+...
journal_title：Vaccine
pub_type： 杂志文章,随机对照试验
doi：10.1016/j.vaccine.2010.08.092
更新日期：2010-10-28 00:00:00
abstract：:An N-terminal peptide of the HIV-1 fusion peptide (FP) with eight amino acid residues (FP8) was conjugated to a recombinant Tetanus Toxoid Heavy Chain Fragment C (rTTHc) as a carrier protein to help boosting immunogenicity against HIV-1. In this rapid communication, a unique algorithm to determine FP-rTTHc conjugation...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2020.04.080
更新日期：2020-06-15 00:00:00
abstract：:Bacterial flagellin is known to induce potent immune response in vertebrate systems via the toll-like receptor (TLR) 5. As a result, flagellin has been studied extensively as a vaccine adjuvant. In a previous study, we examined the vaccine and adjuvant potentials of the flagellin (FliC) of the fish pathogen Edwardsiel...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2010.06.022
更新日期：2010-08-02 00:00:00
abstract：BACKGROUND:Ongoing surveillance is critical to assessing pneumococcal conjugate vaccine (PCV) impact over time. However, robust prospective studies are difficult to implement in resource-poor settings. We evaluated retrospective use of routinely collected data to estimate PCV impact in Rwanda. METHODS:We collected dat...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2016.08.084
更新日期：2016-10-17 00:00:00
abstract：:Several studies have emphasized the importance of an early, highly neutralizing antibody response in the clearance of Hepatitis C virus (HCV) infection. The envelope glycoprotein E2 is a major target for HCV neutralizing antibodies. Here, we compared antibody responses in mice immunized with native soluble E2 (sE2) fr...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2011.02.009
更新日期：2011-04-05 00:00:00
abstract：BACKGROUND AND OBJECTIVES:Public concern about an unsubstantiated link between MMR vaccine and autism stemmed from a 1998 paper by Dr Andrew Wakefield and colleagues, and the substantial media coverage which that work attracted. Though the Wakefield paper is now discredited and an MMR-autism link has never been demonst...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2011.12.127
更新日期：2012-02-27 00:00:00
abstract：INTRODUCTION:The World Health Organization recommends that as part of the polio end-game strategy a dose of inactivated poliovirus vaccine (IPV) be introduced by the end of 2015 in all countries currently using only oral poliovirus vaccine (OPV). Administration of fractional dose (1/5 of full dose) IPV (fIPV) by intrad...
journal_title：Vaccine
pub_type： 杂志文章,随机对照试验
doi：10.1016/j.vaccine.2015.06.071
更新日期：2015-10-26 00:00:00
abstract：:Enterovirus type 71 (EV71) and coxsackievirus A 16 (CA16) are recognized as the major pathogens responsible for human hand-foot-mouth disease. To develop a bivalent EV71-CA16 vaccine, rhesus macaques immunized with two doses of this vaccine via the intradermal route were challenged with EV71 or CA16, and their clinica...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2019.12.057
更新日期：2020-02-18 00:00:00
abstract：:A novel recombinant hepatitis B vaccine, trademarked Sci-B-Vac, was evaluated for safety, tolerability and immunogenicity in an open label trial performed in Singapore. The experimental vaccine, derived from Chinese hamster ovary (CHO) cells, consists of hepatitis B surface antigen (HBsAg) particles harbouring all thr...
journal_title：Vaccine
pub_type： 临床试验,杂志文章,随机对照试验
doi：10.1016/0264-410x(92)90391-v
更新日期：1992-01-01 00:00:00
abstract：:Potent liposomal PorA formulations containing various lipopolysaccharide (LPS) derivatives were developed. The following adjuvants were compared: the commonly used aluminum phosphate (AlPO(4)), and three LPS like adjuvants: monophosphoryl lipid A (MPL), lipopolysaccharide (galE LPS) and the less toxic LPS mutant lpxL1...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2005.06.001
更新日期：2005-10-17 00:00:00
abstract：:Epitopes in HIV polymerase were analyzed by peptide binding to human leukocyte antigen (HLA) A0201 molecules, the most frequent HLA class in the Caucasian population. We found that HIV-1 protease peptides representing both the wild type and anticipated drug resistance variants of the sequence bound well to HLA-A0201. ...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2005.08.019
更新日期：2006-05-22 00:00:00
abstract：:Foot and Mouth Disease (FMD) is an acute disease caused by Foot and Mouth Disease Virus (FMDV) which causes important economy losses, this is why it is necessary to obtain a vaccine that stimulates a rapid and long-lasting protective immune response. Cliptox is a mineral microparticle that in earlier studies has shown...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2010.06.098
更新日期：2010-08-31 00:00:00
abstract：BACKGROUND:Elimination of congenital rubella syndrome depends not only on effective childhood immunization but also on the identification and immunization of rubella susceptible women. We assessed rubella susceptibility among pregnant women and evaluated the adherence and response to postpartum immunization with measle...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2015.02.043
更新日期：2015-04-08 00:00:00
abstract：:Vaccination strategies against Klebsiella pneumoniae have largely focussed on the polysaccharide capsule. However, the large number and high prevalence of individual capsular serotypes limits the widespread applicability of capsule-based vaccines. This study establishes that immunization with purified LPS can protect ...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2008.07.100
更新日期：2008-10-16 00:00:00
abstract：:Six peptides, A, B1, B, C, D and E derived from the primary sequence of Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase (SG3PDH) were selected based on lowest homology to human G3PDH and used for immunization of BALB/c mice. Peptides B1 and D induced immunoglobulin (Ig) G1, IgG2a and IgG2b antibodies that...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/s0264-410x(03)00180-4
更新日期：2003-07-04 00:00:00
abstract：:The 9-valent Human Papillomavirus (HPV) vaccine, 9vHPV, was licensed in the U.S. in December, 2014. We assessed healthcare provider (HCP) awareness of the newly approved vaccine and identified questions HCPs have about the vaccine. As part of a larger study, we used semi-structured interviews to ask 22 pediatric HCPs ...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2016.01.050
更新日期：2016-03-08 00:00:00
abstract：:Chronic lymphocytic leukaemia (CLL) is a common adulthood mature B-cell neoplasm. Infections are the most important cause of mortality in this condition, and Streptococcus pneumoniae has been considered the most important single pathogen. We investigated the immunogenicity of 7-valent pneumococcal conjugate vaccine in...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2007.10.053
更新日期：2007-12-21 00:00:00
abstract：:We compared pertussis surveillance systems of 16 European countries in the period 1998-2002. In twelve out of sixteen countries the system covered the general population. Ten countries relied on WHO case definition for surveillance of pertussis. Eleven countries applied laboratory tests, and eight of them used PCR for...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2006.07.023
更新日期：2007-01-04 00:00:00
abstract：:Cellular as well as humoral immune reactivity were studied in healthy young (< 30 years; n = 12) and older (> 65 years; n = 12) individuals before as well as 1 month after immunization with a trivalent whole virus influenza vaccine. Before vaccination, peripheral blood mononuclear cell proliferation in response to in ...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/s0264-410x(97)88329-6
更新日期：1998-01-01 00:00:00
abstract：:Although few diseases have had a greater impact on human history, currently there is no vaccine available for protection against plague that is licensed by the Food and Drug Administration (FDA). DynPort Vaccine Company LLC, a CSC company (DVC), is managing the advanced development of a recombinant plague vaccine (rF1...
journal_title：Vaccine
pub_type： 杂志文章
doi：10.1016/j.vaccine.2007.01.071
更新日期：2007-04-20 00:00:00
